Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
Context Data regarding gender-specific efficacy of GH on critical endpoints are lacking. There are no randomized, placebo-controlled studies of physiological GH therapy solely in women. Objective Our objective was to determine the effects of physiological GH replacement on cardiovascular risk markers and body composition in women with GH deficiency (GHD). Design This was a 6-month, randomized, placebo-controlled, double-blind study. Setting The study was conducted at the General Clinical Research Center. Study participants 43 women with GHD due to hypopituitarism were included in the study. Intervention Study participants were randomized to receive GH (goal mid-normal serum IGF-1) or placebo. Main outcome measures Cardiovascular risk markers, including high-sensitivity C-reactive protein, tissue plasminogen activator, and body composition, including visceral adipose tissue by cross-sectional computed tomography, were measured. Results Mean daily GH dose was 0.67 mg. The mean IGF-1 sd score increased from -2.5 +/- 0.3 to -1.4 +/- 0.9 (GH) (P Conclusions Low-dose GH replacement in women with GHD decreased total and visceral adipose tissue and improved cardiovascular markers, with a relatively modest increase in IGF-1 levels and without worsening insulin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analyses of 11 randomized trials reported that adult GH replacement resulted in significantly enhanced maximum oxygen uptake and muscle power (169).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [169]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
A, P. T., A, M. G., & W, A. R. (2003) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200305000-00016 · Cited by 1,024
Ridker, P. M., Glynn, R. J., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.20.2007 · Cited by 1,013
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 5×
“J Clin Endocrinol Metab, June 2008, 93(6):2063–2071 jcem.”
BackgroundInfluential
Research works printed but not linked: 1
- Wuster, 1991, Klin Wochenschr, 769
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Nevertheless, several studies including randomized placebo-controlled studies have now shown beneficial effects of GH therapy on visceral fat accumulation and related outcomes in various populations (33, 161, 412, 527, 528).”
BackgroundHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Ismail, I., Keating, S. E., Baker, M. K., & Johnson, N. A. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00931.x · Cited by 345
“GH acts to stimulate adipose tissue directly via hormone sensitive lipase and also indirectly by enhancing insulin sensitivity (56,57).”
BackgroundYuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Self-citationRole of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models
Berryman, D. E., Christiansen, J. S., Johannsson, G., Thorner, M. O., & Kopchick, J. J. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.05.005 · Cited by 288
Gazzaruso, C., Gola, M., Karamouzis, I., Giubbini, R., & Giustina, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2394 · Cited by 151
“Insulin resistance could be exacerbated acutely by GH in GHD (42), whereas it has been shown that GH replacement decreasing visceral fat mass did not worsen insulin resistance (43).”
BackgroundAdult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
“…compared with placebo-treated patients who have a mean 4.3% increase in visceral fat mass over 6 months), suggesting that GHRT may reverse the central adiposity associated with GHD and potentially reduce the increased cardiovascular risk that this body composition carries (Beauregard et al., 2008).”
BackgroundInfluentialThe interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity
Gijsen, H. S., Crowther, N. J., Hough, F. S., & Ferris, W. F. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1211-2 · Cited by 120
Hazem, A., Elamin, M. B., Bancos, I., Malaga, G., Prutsky, G., Domecq, J. P., Elraiyah, T. A., Abu Elnour, N. O., Prevost, Y., Almandoz, J. P., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0558 · Cited by 97
Age-Related Changes in Body Composition of Bovine Growth Hormone Transgenic Mice
Palmer, A. J., Chung, M., List, E. O., Walker, J., Okada, S., Kopchick, J. J., & Berryman, D. E. (2008) · Endocrinology · doi:10.1210/en.2008-1199 · Cited by 111
Effects of Recombinant Human Growth Hormone Therapy in Obesity in Adults: A Metaanalysis
Mekala, K. C., & Tritos, N. A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1357 · Cited by 97
Diagnosis and treatment of growth hormone deficiency in adults
Kargi, A. Y., & Merriam, G. R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.77 · Cited by 95
Silveira, É. A., Vaseghi, G., Santos, A. S. E. A. D. C., Kliemann, N., Masoudkabir, F., Noll, M. A., Mohammadifard, N., Sarrafzadegan, N., & de Oliveira, C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239042 · Cited by 94
Donges, C. E., Duffield, R., Guelfi, K. J., Smith, G. C., Adams, D. R., & Edge, J. A. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2012-0443 · Cited by 74
Miller, K. K., Wexler, T., Fazeli, P., Gunnell, L., Graham, G. J., Beauregard, C., Hemphill, L., Nachtigall, L., Loeffler, J., Swearingen, B., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1611 · Cited by 66
Self-citationSode-Carlsen, R., Farholt, S., Rabben, K. F., Bollerslev, J., Schreiner, T., Jurik, A. G., Christiansen, J. S., & Höybye, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0907 · Cited by 65
Deepak, D. S., Daousi, C., Javadpour, M., Clark, D. J., PERRY, Y. S., Pinkney, J. H., & MacFarlane, I. A. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.02.002 · Cited by 62
Growth Hormone and the Cardiovascular System
Palmeiro, C., Anand, R. G., Dardi, I. K., Balasubramaniyam, N., Schwarcz, M., & Weiss, I. A. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e318248a3e1 · Cited by 60
“Markers such as C-reactive protein and tissue plasminogen activator were significantly decreased after treatment with GH replacement in randomized trial of 43 women.(129)”
BackgroundBredella, M. A., Gerweck, A. V., Lin, E., Landa, M. G., Torriani, M., Schoenfeld, D., Hemphill, L., & Miller, K. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2063 · Cited by 55
Self-citationBredella, M. A., Lin, E., Brick, D. J., Gerweck, A. V., Harrington, L. M., Torriani, M., Thomas, B. J., Schoenfeld, D., Breggia, A., Rosen, C. J., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1068 · Cited by 53
Self-citationMetabolic alterations in paediatric GH deficiency
Rothermel, J., & Reinehr, T. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.11.004 · Cited by 54
Kim, J. H., Chae, H. W., Chin, S. O., Ku, C. R., Park, K. H., Lim, D. J., Kim, K. J., Lim, J. S., Kim, G., Choi, Y. M., et al. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.272 · Cited by 52
“It was further reported that GH replacement led to a decrease preferentially in visceral fat [64] and an increase in lean body mass [27,65], and improvements in muscle function [65] and lipid metabolism [66] can be expected as well.”
BackgroundOPPORTUNITY : a large-scale randomized clinical trial of growth hormone in hemodialysis patients
Kopple, J. D., Cheung, A. K., Christiansen, J. S., Djurhuus, C., Nahas, M. E., Feldt‐Rasmussen, B., Mitch, W. E., Wanner, C., Göthberg, M., & Ikizler, T. A. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr363 · Cited by 47
“hGH administration has been shown to decrease serum CRP in other patient populations, and similar mechanisms might be operative in MHD patients [36, 37].”
The Immune System in Obesity: Developing Paradigms Amidst Inconvenient Truths
Agrawal, M., Kern, P. A., & Nikolajczyk, B. S. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0917-9 · Cited by 48
Cardiovascular alterations in adult GH deficiency
Somma, C. D., Scarano, E., Savastano, S., Savanelli, M. C., Pivonello, R., & Colao, A. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.03.005 · Cited by 48
Newman, C. B., Carmichael, J. D., & Kleinberg, D. L. (2014) · Pituitary · doi:10.1007/s11102-014-0571-z · Cited by 42
“[38] 2008 20:23 0.”
Growth hormone controls lipolysis by regulation of FSP27 expression
Sharma, R., Luong, Q. V., Sharma, V. M., Harberson, M. T., Harper, B., Colborn, A., Berryman, D. E., Jessen, N., Jørgensen, J. O. L., Kopchick, J. J., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0282 · Cited by 42
Dichtel, L. E., Corey, K. E., Haines, M. S., Chicote, M. L., Kimball, A., Colling, C., Simon, T. G., Long, M. T., Husseini, J. S., Bredella, M. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac405 · Cited by 38
Self-citationLin, E., Wexler, T. L., Nachtigall, L., Tritos, N., Swearingen, B., Hemphill, L., Loeffler, J., Biller, B. M. K., Klibanski, A., & Miller, K. K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04361.x · Cited by 37
Self-citationErman, A., Veilleux, A., Tchernof, A., & Goodyer, C. G. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.23 · Cited by 42
Profka, E., Giavoli, C., Bergamaschi, S., Ferrante, E., Malchiodi, E., Sala, E., Verrua, E., Rodari, G., Filopanti, M., Beck‐Peccoz, P., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0196-0 · Cited by 37
Ramos-Levi, A. M., & Marazuela, M. (2018) · Endocrine · doi:10.1007/s12020-017-1492-1 · Cited by 35
Fasting Levels of High-Sensitivity Growth Hormone Predict Cardiovascular Morbidity and Mortality
Hallengren, E., Almgren, P., Engström, G., Hedblad, B., Persson, M., Suhr, J., Bergmann, A., & Melander, O. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.063 · Cited by 34
Growth hormone deficiency in treated acromegaly
Mazziotti, G., Marzullo, P., Doga, M., Aimaretti, G., & Giustina, A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.10.005 · Cited by 33
Cordido, F., García‐Buela, J., Sangiao‐Alvarellos, S., Martínez, T., & Vidal, O. (2010) · Mediators of Inflammation · doi:10.1155/2010/434562 · Cited by 35
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2010, Article ID 434562, 8 pages doi:10.1155/2010/434562”
BackgroundInfluentialImpact of Growth Hormone on Regulation of Adipose Tissue
Troike, K. M., Henry, B. E., Jensen, E., Young, J. A., List, E. O., Kopchick, J. J., & Berryman, D. E. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160027 · Cited by 33
Somma, C. D., Pivonello, R., Pizza, G., Rosa, A. D., Lombardi, G., Colao, A., & Savastano, S. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346577 · Cited by 28
Meienberg, F., Yee, M. S., Johnston, D. G., Cox, J., Robinson, S., Bell, J. D., Thomas, E. L., Taylor-Robinson, S. D., & Godsland, I. F. (2016) · Clinical Endocrinology · doi:10.1111/cen.13042 · Cited by 27
The Glycoproteomics–MS for Studying Glycosylation in Cardiac Hypertrophy and Heart Failure
Yang, S., Chatterjee, S. B., & Cipollo, J. F. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700075 · Cited by 27
Sheehan syndrome: Cardiovascular and metabolic comorbidities
Laway, B. A., & Baba, M. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1086731 · Cited by 30
Bhat, M. A., Laway, B. A., Shah, Z. A., Wani, A. I., & Mubarik, I. (2014) · Pituitary · doi:10.1007/s11102-014-0575-8 · Cited by 28
Yuen, K. C. J., Roberts, C. T., Frystyk, J., Rooney, W. D., Pollaro, J., Klopfenstein, B. J., & Purnell, J. Q. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1532 · Cited by 24
“3 mg/d decreases fat mass and increases lean body mass, insulin sensitivity remains unchanged (2, 3), improved (4, 5), or worsened (6, 7).”
BackgroundNewman, C. B., Frisch, K. A., Rosenzweig, B. P., Roubenoff, R., Rey, M. J., Kidder, T., Kong, Y., Pursnani, A. K., Sedlis, S. P., Schwartzbard, A. Z., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1204 · Cited by 24
Hormonal factors in the control of the browning of white adipose tissue
Hu, J., & Christian, M. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0017 · Cited by 23
“Adults and children with GH deficiency have increased fat mass, while treatment of GH-deficient patients with recombinant human GH decreases fat mass [88], [89], [90].”
BackgroundReinehr, T., Lindberg, A., Kołtowska‐Häggström, M., & Ranke, M. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12464 · Cited by 23
Russell, M., Bredella, M. A., Tsai, P., Mendes, N., Miller, K. K., Klibanski, A., & Misra, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0380 · Cited by 23
Self-citationThe diagnosis and treatment of growth hormone deficiency in adults
Clemmons, D. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833b6bc7 · Cited by 22
Li, L., Ren, W., Li, J., Liu, J., Wang, L., Zheng, X., Liu, D., Li, S., Souvenir, R., & Tang, J. (2012) · Endocrine · doi:10.1007/s12020-012-9697-9 · Cited by 21
Growth hormone and HIV infection: Contribution to disease manifestations and clinical implications
Falutz, J. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.11.001 · Cited by 23
Valassi, E., Brick, D. J., Johnson, J. C., Biller, B. M. K., Klibanski, A., & Miller, K. K. (2012) · Endocrine Practice · doi:10.4158/ep11134.or · Cited by 19
“The recruitment procedures and the design of the studies have been reported elsewhere (4,14).”
BackgroundMethodSelf-citationOsganian, S. A., Subudhi, S., Masia, R., Drescher, H. K., Bartsch, L. M., Chicote, M. L., Chung, R. T., Gee, D. W., Witkowski, E. R., Bredella, M. A., et al. (2022) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2022.101482 · Cited by 18
Giagulli, V. A., Castellana, M., Perrone, R., Guastamacchia, E., Iacoviello, M., & Triggiani, V. (2017) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530317666170919121729 · Cited by 18
“Considering each study individually, D value was very low for several studies [15, 16], and very high for others [10, 17-20].”
BackgroundStanley, T. L., Falutz, J., Mamputu, J., Soulban, G., Potvin, D., & Grinspoon, S. K. (2011) · AIDS · doi:10.1097/qad.0b013e328347f3f1 · Cited by 17
“Previous reports have indicated that GH treatment decreases tPA antigen in non-HIV-infected individuals [16,17], but it has been unclear whether this is a direct effect of GH itself or whether decreased tPA antigen may be mediated by decreased abdominal adiposity.”
Karastergiou, K., Bredella, M. A., Lee, M., Smith, S. R., Fried, S. K., & Miller, K. K. (2016) · Obesity · doi:10.1002/oby.21460 · Cited by 16
“tial effect on visceral than on subcutaneous abdominal depots (9,10).”
BackgroundSelf-citationBonert, V. S., & Melmed, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00004-0 · Cited by 21
Chihara, K., Fujieda, K., Shimatsu, A., Miki, T., & Tachibana, K. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.01.003 · Cited by 14
“reported a correlation between changes in IGF-I SDS and percent trunk fat mass among women [14].”
BackgroundTREATMENT OF ADULT GROWTH HORMONE DEFICIENCY: WHO, WHY AND HOW? A REVIEW.
Alexopoulou, O., Abs, R., & Maiter, D. M. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.002 · Cited by 14
“Some studies have shown that these changes are more marked in men than in women (61;62) but recently very signifi cant GH effects have been shown on the adipose visceral tissue in women, even at low GH doses (63).”
BackgroundGraham, M. R., Evans, P., Thomas, N. E., Davies, B., & Baker, J. S. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/11312100-000000000-00000 · Cited by 16
Growth hormone status predicts left ventricular mass in patients after cure of acromegaly
Wexler, T., Durst, R. Y., McCarty, D., Picard, M. H., Gunnell, L., Omer, Z. B., Fazeli, P. K., Miller, K. K., & Klibanski, A. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.05.003 · Cited by 14
Self-citationWang, C., Huang, H., Zhao, C., Zhao, J., Xiong, R., Jin, R., & Bai, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-871 · Cited by 13
“21037/apm-20-871 reduce the arteriosclerosis index, decrease the mortality rate and the risk of cardiovascular disease, and improve a patient’s quality of life (18,19).”
BackgroundThe effect of growth hormone on bioactive IGF in overweight/obese women
Dichtel, L. E., Bjerre, M., Haines, M. S., Bredella, M. A., Gerweck, A. V., Russell, B. M., Frystyk, J., & Miller, K. K. (2018) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2018.03.003 · Cited by 12
Self-citationLipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 13
“The effect of GH replacement therapy on serum lipids in patients with GHD is controversial, with some studies reporting improvements in total and LDL cholesterol [28, 30 ] whereas others showed no change [31].”
BackgroundResultNutrition, obesity and hormones
Giammanco, M., Lantieri, L., Leto, G., Pescia, F., & Majo, D. D. (2018) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2018.7755 · Cited by 15
Xia, J., Li, L., Ren, W., Zheng, X., Liu, C., Li, J., Chen, T., Li, X., Wang, L., & Hu, Y. (2015) · Europe PMC (PubMed Central) · Cited by 8
Køber, L., Rustom, R., Wiedmann, J., Kappelgaard, A., Nahas, M. E., & Feldt‐Rasmussen, B. (2010) · Nephron Clinical Practice · doi:10.1159/000313038 · Cited by 9
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 8
Wang, Y., Zheng, X., Xie, X., Qian, W., Ren, Z., Chen, Y., Wu, X., Liao, K. T., & Ren, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110875 · Cited by 6
Effects of growth hormone withdrawal in obese premenopausal women
Lin, E., Bredella, M. A., Gerweck, A. V., Landa, M. G., Schoenfeld, D., Utz, A. L., & Miller, K. K. (2012) · Clinical Endocrinology · doi:10.1111/cen.12102 · Cited by 5
Self-citationEspinosa-Cárdenas, E., Salame, L., Marrero–Rodríguez, D., Romero-Nieves, A.-M., Cuenca, D., Castelán-Martínez, O. D., Mendoza, V., Ponce-Navarrete, G., Salcedo, M., Luque-Leòn, E., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1794-y · Cited by 5
Arosio, M., Arnaldi, G., Gasco, V., Giavoli, C., Puxeddu, E., Vettor, R., Ambrosio, M. R., Gallinari, P., Zouater, H., Fedeli, P., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01308-3 · Cited by 5
Fazeli, P. K., Teoh, J. G., Lam, E. L., Gerweck, A. V., Wexler, T., Teo, E. P., Russell, B. M., Durst, R. Y., McCarty, D., Weiner, R. B., et al. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.12.003 · Cited by 5
Self-citationHerman-Bonert, V. S., & Melmed, S. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10004-5 · Cited by 5
Topaloğlu, O., Gökay, F., Koparal, S. S., Akbaba, G., Mete, T., Arduç, A., Tuna, M. M., Yalçın, Y., Yavuz, H. C., Berker, D., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0027 · Cited by 4
Borson‐Chazot, F., Chabre, O., Salenave, S., Klein, M., de la Perrière, A. B., Reznik, Y., Kerlan, V., Hacques, E., & Villette, B. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.11.007 · Cited by 4
Varlamov, E. V., & Fleseriu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00019-6 · Cited by 6
Pei, Z., Wang, X., Yang, C., Dong, M., & Wang, F. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3899356 · Cited by 3
“It has been established that rhGH influences fat distribution; rhGH-replacement therapy administered to the hypopituitary adults decreases abdominal fat [33, 34]; rhGH also affects adipocyte metabolism by regulating fatty acid storage and release [35].”
BackgroundMuraoka, T., Hizuka, N., Fukuda, I., Ishikawa, Y., & Ichihara, A. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0528 · Cited by 4
“Similar metabolic disorders including visceral adiposity and insulin resistance are observed in patients with adult growth hormone (GH) deficiency, and GH replacement therapy ameliorates those abnormalities in these patients [4].”
BackgroundCooper, O. B., & Kim, S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf072 · Cited by 2
“Some of this clinical inertia may be due, at least in part, to concerns surrounding potential growth of residual tumor and of the risk for new-onset T2DM with GH replacement, even though evidence for both risks are conflicting [11-14].”
Salagre, D., Mosqueda, C. V. A., Aouichat, S., & Agil, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091247 · Cited by 2
“GH replacement therapy in humans restores basal metabolic rate, reduces visceral fat and waist circumference, and improves lipid profiles, glucose tolerance, and insulin sensitivity, recovering body composition [112] and highlighting GH’s link with central obesity and diabetes.”
Pastuszak, A. W., Lai, W. S., Khera, M., & Lipshultz, L. I. (2012) · Open Journal of Urology · doi:10.4236/oju.2012.23017 · Cited by 2
Klinc, A., Janež, A., & Jensterle, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052010 · Cited by 2
“In addition, a few studies, including ours, have established a negative between IGF-1 and hs-CRP levels [4,17,21,23], supporting a direct effect of GHRT on However, suggesting systemic composition. study is the first to demonstrate the association between long-term maintenance of IGF-1 SDS within…”
Adult Growth Hormone Deficiency
Vaughan, T. B., Riley, K. O., & Blevins, L. S. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch5 · Cited by 2
Ludlam, W. H. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79004-8 · Cited by 1
Effect of Growth Hormone Deficiency on the Cardiovascular System
Magfirah, I., Soelistijo, S. A., Novida, H., & Ardiany, D. (2017) · Surabaya International Physiology Seminar (SIPS) · doi:10.5220/0007338903420348 · Cited by 1
“The risk of thrombosis is very high, therefore increasing the risk of cardiovascular morbidity and mortality (Beauregard et al., 2008).”
BackgroundMelmed, S. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00014-9 · Cited by 3
Der Effekt von Wachstumshormon auf die menschlichen Alterungsprozesse. Teil 2
Klentze, M. (2018) · Journal für Gynäkologische Endokrinologie/Österreich · doi:10.1007/s41974-018-0059-3
“(2008) konnten in einer 6 Monate laufenden placebokontrollierten Studie eine Verminderung von viszeralem Fett (9%) beobachten, verglichen mit der Placebogruppe, die um 4,7% an viszeralem Fett zunahm [10].”
BackgroundIshak, M. E., & Baig, U. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.pituitary_overview
(2011) · CRC Press eBooks · doi:10.1201/b10790-15
Beneficial effects of GHRT in women with hypopituitarism
(2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0877
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00017-0
Der Effekt von Wachstumshormon auf die menschlichen Alterungsprozesse. Teil 2
Klentze, M. (2018) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-018-0064-y
Quarde, A. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch1
Déficit de hormona de crecimiento en el adulto
Rosero, M. E. P., Mejía, A. F., & Abreu-Lomba, A. (2024) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10228
Cardiovascular and Metabolic Comorbidities in Pituitary Disorders
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5034-2
Bann, D. (2013) · UCL Discovery (University College London)
Déficit de hormona de crecimiento en la época de transición y en el adulto
Álvarez‐Escolá, C., Cárdenas‐Salas, J., & Fajardo, C. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00005-8
Metadata
- Authors
- Beauregard, C., Utz, A. L., Schaub, A. E., Nachtigall, L., Biller, B. M. K., Miller, K. K., & Klibanski, A.
- Affiliations
- Harvard University (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-06-01
- Volume
- 93
- Issue
- 6
- Pages
- 2063-2071
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2435650
- OpenAlex
- W1968009970
- Cited by
- 99
- References
- 67
- Citations by year
- 2025: 3 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 8 · 2017: 9 · 2016: 4 · 2015: 3 · 2014: 11 · 2013: 8 · 2012: 9
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK040561)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- growth hormone replacement therapy, growth hormone deficiency, hypopituitarism, women, visceral adipose tissue, body composition, cardiovascular risk markers, C-reactive protein, tissue plasminogen activator, insulin-like growth factor I, insulin resistance, cholesterol, HDL cholesterol, inflammation, fat loss
- MeSH terms
- Adult, Aged, Body Composition, Cardiovascular Diseases, Double-Blind Method, Female, Glucose, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Lipoproteins, Middle Aged, Placebos, Risk Factors, Growth Hormone, Biomarkers, Human Growth Hormone, Intra-Abdominal Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.